Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)- 17-demethoxygeldanamycin (NSC 707545) in CD 2f 1 mice and fischer 344 rats

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 1, 2002, Pages 7-19

  Egorin, Merrill J ^a,b   Lagattuta, Theodore F ^a,b   Hamburger, Deborah R ^a,b   Covey, Joseph M ^a,b,c   White, Kevin D ^a,b,d   Musser, Steven M ^a,b,d   Eiseman, Julie L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Ansamycin; Geldanamycin; HSP90; Pharmacokinetics

Indexed keywords

17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; DRUG METABOLITE; GELDANAMYCIN; NSC 707545; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TISSUE LEVEL; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION; ANIMAL TISSUE; AREA UNDER THE CURVE; BOLUS INJECTION; DRUG BILE LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE STRAIN; RAT STRAIN; SPECIES COMPARISON;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BENZOQUINONES; BILE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EATING; FEMALE; HALF-LIFE; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED STRAINS; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; QUINONES; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 0036139023     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0380-8     Document Type: Article

References (71)

1. Proteasome inhibitors: A novel class of potent and effective antitumor agents
2. Signal transduction pathway targets for anticancer drug discovery
3. Human plasma pharmacokinetics of the novel antitumor agent, 17-allylaminogeldanamycin (AAG) using a new HPLC-based analytic assay
4. A Bayesian extension of the minimal AIC procedures of autoregressive model fitting
5. erbB2, and Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
6. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome
7. An overview of topoisomerase I-targeting agents
8. Telomerase as a possible target for anticancer therapy
9. Development and validation of pharmacodynamic end points in tumor and normal tissue to assess the effect of the HSP90 molecular chaperone inhibitor 17-allylamino-17-demethoxy geldanamycin (17-AAG)
10. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints
11. Geldanamycin selectively destabilizes and conformationally alters mutated p53
12. Cell cycle molecular targets in novel anticancer drug discovery
13. Degradation of heterotrimeric Galpha(o) subunits via the proteosome pathway is induced by the hsp90-specific compound geldanamycin
14. erbB2 binds to GRP94 in vivo
15. DNA array technology in the molecular pharmacology of colorectal cancer
16. Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus
17. A program package for simulation and parameter estimation in pharmacokinetic systems
18. Geldanamycin prevents nuclear translocation of mutant p53
19. Metabolism of 17-(allylamino)- 17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations
20. 1 mice
21. A phase I trial of 17-allyl-aminogeldanamycin in patients with advanced cancer
22. Anticancer drug targets: Growth factors and growth factor signaling
23. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
24. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation
25. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines
26. The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load
27. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
28. Anticancer drug targets: Approaching angiogenesis
29. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells
30. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins
31. Binding of benzoquinoid ansamycins to pl00 correlates with their ability to deplete the erbB2 gene product p185
32. Polyubiquitination and proteasomal degradation of the p185c-erbB2 receptor protein-tyrosine kinase induced by geldanamycin
33. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
34. Phase I trial of 17-(allylamino)-17-demethoxygeladnamycin (17AAG) in patients (Pts) with advanced solid malignancies
35. Geldanamycin as a potent anti-cancer agent: Its molecular target and biochemical activity
36. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
37. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
38. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase
39. Geldanamycin inhibition of 3-methylcholanthrene-induced rat embryo cell transformation
40. LAGRAN program for area and moments in pharmacokinetic analysis
41. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
42. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases
43. Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives
44. Evolving approaches to cancer drug discovery and development at the National Cancer Institute
45. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
46. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
47. erbB-2 Oncogene inhibition by geldanamycin derivatives: Synthesis, mechanism of action, and structureactivity relationships
48. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives
49. The benzoquinone ansamycin 17-allylamino- 17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
50. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association
51. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1MEK-mitogen-activated protein kinase signaling pathway
52. Geldanamycin-induced destabilization of Raf-q involves the proteasome
53. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
54. Anticancer drug targets: Cell cycle and checkpoint control
55. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent
56. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinases
57. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
58. Preclinical pharmacological evaluation of geldanamycin as an antitumor agent
59. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation
60. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus
61. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
62. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
63. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
64. v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
65. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
66. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent
67. Phase I pharmacokinetic study of 17- (allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors
68. Sensitivity of mature erbB-2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein hsp90
69. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group
70. Disruption of the EF-2 kinase/hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin
71. A comparison of numerical integrating algorithms by trapezoidal, LaGrange and spline approximation